文献速递脊柱外科骨质疏松与代谢性骨病创伤骨科

近期脊髓损伤对OPG/RANKL系统的影响及其与骨丢失和地舒单抗治疗反应的关系

Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
PubMed 文献 · Osteoporos Int · 2017-06-04

该前瞻性研究纳入23例近期完全性脊髓损伤男性,比较其与健康对照的OPG/RANKL水平,并评估地舒单抗治疗前后变化。基线RANKL升高且与伤后天数及6个月全髋BMD丢失相关;地舒单抗治疗后67%患者RANKL转为检测不到,且这部分患者股骨BMD和骨标志物反应更好。提示RANKL在脊髓损伤诱导的骨质疏松中起促进作用。

要点

  • 近期完全性脊髓损伤男性基线RANKL水平高于健康对照,且与伤后天数及6个月全髋BMD丢失相关。
  • 地舒单抗治疗后67%患者RANKL转为检测不到,该组股骨BMD和骨标志物反应优于仍可检测到RANKL者。
  • 治疗期间PTH升高与RANKL变化呈负相关。

核心结论

  • 脊髓损伤后RANKL水平升高,与股骨近端BMD丢失相关,地舒单抗治疗后转为检测不到。
  • 地舒单抗预防损伤平面以下骨丢失的效果,尤其在治疗期间RANKL检测不到的患者中,提示RANKL在该过程中起促进作用。

研究设计与样本

  • 前瞻性纳入23例近期完全性脊髓损伤男性,并与健康对照组比较。
  • 在基线、随访6个月、开始地舒单抗前及治疗后6个月评估血清OPG、RANKL、骨转换标志物(PINP、骨ALP、CTX)和BMD。

主要发现

  • 基线时脊髓损伤患者RANKL水平高于对照组,且与伤后天数及6个月时全髋BMD丢失相关。
  • 基线时OPG水平与对照组相似。
  • 地舒单抗治疗后OPG无变化,67%患者RANKL转为检测不到。
  • 地舒单抗治疗6个月时,RANKL检测不到的患者股骨BMD和骨标志物反应优于RANKL可检测到的患者。
  • 治疗期间PTH水平升高与RANKL变化呈负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: There is marked bone loss after spinal cord injury (SCI); however, its pathogenesis and clinical management remain unclear. The increased circulating levels of receptor activator of nuclear factor kB ligand (RANKL) associated with bone loss shortly after SCI and the prevention of bone loss with denosumab treatment suggest a contributory role of RANKL in SCI-induced osteoporosis. INTRODUCTION: Bone turnover and bone loss are markedly increased shortly after SCI. However, the pathogenesis and clinical management of this process remain unclear, especially the role of the osteoprotegerin (OPG)/RANKL system in this disorder. The aim of this study was to analyze serum levels of OPG and RANKL in bone loss associated with recent SCI and the effect of denosumab treatment on these mediators. METHODS: Twenty-three males with recent complete SCI were prospectively included. Serum OPG and RANKL levels, bone turnover markers (PINP, bone ALP, CTX), and bone mineral density (BMD) were assessed at baseline, at 6 months of follow-up, prior to initiating denosumab, and 6 months after treatment. The results were compared with a healthy control group. RESULTS: At baseline, SCI patients showed higher RANKL levels vs. controls which were correlated with days-since-SCI and total hip BMD loss at 6 months. OPG levels were similar to controls at baseline. After denosumab treatment, OPG showed no changes, whereas RANKL levels became undetectable in 67% of patients. Patients with undetectable RANKL during treatment showed better response in femoral BMD and bone markers vs. patients with detectable RANKL at 6 months of denosumab. Increased parathormone (PTH) levels during treatment were negatively correlated with RANKL changes. CONCLUSIONS: RANKL levels are increased after SCI and related to BMD loss at the proximal femur, becoming undetectable after denosumab treatment. The effect of denosumab on preventing sublesional bone loss, especially in patients with undetectable levels during treatment, suggests a contributory role of RANKL in this process.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Gifre L, Ruiz-Gaspà S, Carrasco JL, et al. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy. Osteoporos Int. 2017. PMID: 28580511. doi:10.1007/s00198-017-4090-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。